BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33589754)

  • 21. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
    Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
    Burns MA; Place AE; Stevenson KE; Gutiérrez A; Forrest S; Pikman Y; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28719. PubMed ID: 33026184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
    Selim A; Alvaro F; Cole CH; Fraser CJ; Mechinaud F; O'Brien TA; Shaw PJ; Tapp H; Teague L; Nivison-Smith I; Moore AS
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27812. PubMed ID: 31111633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
    Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
    Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
    Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome.
    Taga T; Saito AM; Kudo K; Tomizawa D; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Tawa A; Shimada A; Taki T; Kigasawa H; Koh K; Adachi S
    Blood; 2012 Aug; 120(9):1810-5. PubMed ID: 22776818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
    Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; Dahl GV; Bowman WP; Taub JW; Degar B; Leung W; Downing JR; Pui CH; Rubnitz JE; Campana D
    J Clin Oncol; 2012 Oct; 30(29):3625-32. PubMed ID: 22965955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
    Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
    Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
    Huo Y; Guan XM; Dou Y; Wen XH; Guo YX; Shen YL; An XZ; Yu J
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Nov; 23(11):1111-1118. PubMed ID: 34753542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.